若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

Rolipram

cAMP通路激活剂;抑制4型环核苷酸磷酸二酯酶(PDE4)

产品号 #(选择产品)

产品号 #73382_C

cAMP通路激活剂;抑制4型环核苷酸磷酸二酯酶(PDE4)

总览

Rolipram是一种具有细胞渗透性的选择性4型环核苷酸磷酸二酯酶(PDE4)抑制剂,该酶介导环磷酸腺苷(cAMP)的降解。Rolipram对PDE4同工酶A(IC₅₀=3 nM)的抑制作用优于对PDE4同工酶B和D(IC₅₀=130 nM和240 nM;MacKenzie和Houslay)等其他同工酶的抑制作用。它通过抑制PDE4B和/或PDE4D同工酶来抑制干扰素IFN-γ刺激的p38丝裂原活化蛋白(MAP)激酶的磷酸化(MacKenzie和Houslay)。

分化
·增强BMP-2诱导的小鼠间充质干细胞(MSC)的成骨分化(Munisso等)
·诱导人骨髓来源间充质干细胞的神经分化(Alexanian等)

重编程
·结合A83-01、CHIR99021、丁酸钠、LPA、SP600125和外源性OCT4表达,诱导成人人类真皮成纤维细胞(AHDF)重编程为诱导神经干细胞(Zhu等)

疾病建模
·促进小鼠缺血模型中新形成的小鼠海马神经元的存活(Sasaki等)
·逆转C57BL/6J小鼠精神分裂症模型中苯丙胺引起的听觉诱发电位降低(Maxwell等)

免疫学
·通过抑制白细胞功能,抑制人嗜酸性粒细胞中C5a刺激的白三烯C4(LTC4)合成(Tenor等)
·抑制人单核细胞中脂多糖(LPS)诱导的肿瘤坏死因子(TNF)的合成(Souness等)

细胞类型
间充质干/祖细胞,单核细胞,神经干/祖细胞,神经元,成骨细胞
 
种属
人,小鼠,非人灵长类,其它细胞系,大鼠
 
应用
分化,重编程
 
研究领域
疾病建模,免疫,干细胞生物学
 
CAS 编号
61413-54-5
 
化学式
C₁₆H₂₁NO₃
 
纯度
≥98%
 
通路
cAMP
 
靶点
PDE
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
Rolipram
Catalog #
73384, 73382
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Rolipram
Catalog #
73384, 73382
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (3)

文献 (8)

Small molecules enable OCT4-mediated direct reprogramming into expandable human neural stem cells. Zhu S et al. Cell research 2014
Cilomilast enhances osteoblast differentiation of mesenchymal stem cells and bone formation induced by bone morphogenetic protein 2. Munisso MC et al. Biochimie 2012

Abstract

A rapid and efficient method to stimulate bone regeneration would be useful in orthopaedic stem cell therapies. Rolipram is an inhibitor of phosphodiesterase 4 (PDE4), which mediates cyclic adenosine monophosphate (cAMP) degradation. Systemic injection of rolipram enhances osteogenesis induced by bone morphogenetic protein 2 (BMP-2) in mice. However, there is little data on the precise mechanism, by which the PDE4 inhibitor regulates osteoblast gene expression. In this study, we investigated the combined ability of BMP-2 and cilomilast, a second-generation PDE4 inhibitor, to enhance the osteoblastic differentiation of mesenchymal stem cells (MSCs). The alkaline phosphatase (ALP) activity of MSCs treated with PDE4 inhibitor (cilomilast or rolipram), BMP-2, and/or H89 was compared with the ALP activity of MSCs differentiated only by osteogenic medium (OM). Moreover, expression of Runx2, osterix, and osteocalcin was quantified using real-time polymerase chain reaction (RT-PCR). It was found that cilomilast enhances the osteoblastic differentiation of MSCs equally well as rolipram in primary cultured MSCs. Moreover, according to the H89 inhibition experiments, Smad pathway was found to be an important signal transduction pathway in mediating the osteogenic effect of BMP-2, and this effect is intensified by an increase in cAMP levels induced by PDE4 inhibitor.
Transplanted neurally modified bone marrow-derived mesenchymal stem cells promote tissue protection and locomotor recovery in spinal cord injured rats. Alexanian AR et al. Neurorehabilitation and neural repair 2011

Abstract

BACKGROUND: Stem cell-based therapy for repair and replacement of lost neural cells is a promising treatment for central nervous system (CNS) diseases. Bone marrow (BM)-derived mesenchymal stem cells (MSCs) can differentiate into neural phenotypes and be isolated and expanded for autotransplantation with no risk of rejection. OBJECTIVE: The authors examined whether transplanted neurally induced human MSCs (NI hMSCs), developed by a new procedure, can survive, differentiate, and promote tissue protection and functional recovery in injured spinal cord (ISC) rats. METHODS: Neural induction was achieved by exposing cells simultaneously to inhibitors of DNA methylation, histone deacetylation, and pharmacological agents that increased cAMP levels. Three groups of adult female Sprague-Dawley rats were injected immediately rostral and caudal to the midline lesion with phosphate-buffered saline, MSCs, or NI hMSCs, 1 week after a spinal cord impact injury at T-8. Functional outcome was measured using the Basso Beattie Bresnahan (BBB) locomotor rating scale and thermal sensitivity test on a weekly basis up to 12 weeks postinjury. Graft integration and anatomy of spinal cord was assessed by stereological, histochemical, and immunohistochemical techniques. RESULTS: The transplanted NI hMSCs survived, differentiated, and significantly improved locomotor recovery of ISC rats. Transplantation also reduced the volume of lesion cavity and white matter loss. CONCLUSION: This method of hMSC modification may provide an alternative source of autologous adult stem cells for CNS repair.

更多信息

更多信息
种属 Human, Mouse, Non-Human Primate, Other, Rat
Cas Number 61413-54-5
Chemical Formula C₁₆H₂₁NO₃
纯度 ≥ 98%
Target PDE
Pathway cAMP
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.